Do I Need to Tell My Doctor PCOS Is Now PMOS?

The short answer

You do not have to tell anyone. Nothing about your care depends on you being the one to break the news.

If you walk in and say “PCOS”, every clinician you meet will know exactly what you mean, and will for years. If you walk in and say “PMOS” to a doctor who has not read the announcement, you will spend two minutes of a ten-minute appointment explaining a name instead of a symptom. Neither version changes what happens next.

What actually changed

In 2026, a global consensus process published in The Lancet renamed polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome (PMOS). Fifty-six academic, clinical and patient organisations took part, and the process drew on survey responses from 14,360 people with the condition and health professionals across every world region.

The reasoning was that “polycystic ovary” describes a feature that is not a cyst, is not present in everyone with the condition, and says nothing about the endocrine and metabolic parts that dominate day-to-day life. The consensus paper is explicit that the goal was accuracy — dropping “cystic” and naming the endocrine, metabolic and ovarian dysfunction that is actually there.

What the paper did not do is touch biology, thresholds or treatment. It is a naming and implementation document. Diagnostic criteria still come from the 2023 international guideline, and they are the same today as they were the day before the announcement. If you want the longer version, start with what the PCOS to PMOS change means or why PCOS was renamed.

What the rename does and does not change

The consensus group deliberately chose an “evolution rather than transformation” rollout, with a transition period, clinician education, and alignment with health-system coding still under way. That means the old name will be correct in clinical use for a long time yet.

In your care	Before the rename	Now	Raise it?
Your diagnosis	PCOS, by Rotterdam criteria	Same condition, same criteria	No
The code on your file	ICD-10 E28.2, “polycystic ovarian syndrome”	Still E28.2 as of this writing; classification alignment is in progress	No
Prescriptions	Metformin, combined pill, letrozole, spironolactone	Unchanged — no relabelling, no new indication	No
Past scans, letters, referrals	Say PCOS	Still say PCOS, still valid	No
Insurance and prior authorisation	Filed under PCOS	Filed under PCOS	No
Searching research or trials	“PCOS”	Search both terms — indexing is mid-transition	Only for yourself
A clinician who is new to you	—	May use either term	One sentence, if it helps

When it is worth saying out loud

There are four situations where naming the change earns its two minutes. In each one, the point is not the terminology — it is the misunderstanding the old name was causing.

1. Someone tells you your ovaries look normal, so you cannot have it. This is the single most useful case. Polycystic ovarian morphology is one of three Rotterdam features, and you only need two. A normal-looking ultrasound does not rule the condition out.

2. You are switching countries, clinics or specialties. New notes, new coder, new phrasing. Say both names once and it never comes up again.

3. You are looking for a clinical trial or reading recent papers. Search indexing is mid- transition, so a search for one term will miss work filed under the other.

4. You are being handed off from paediatric to adult care. Adolescent diagnosis already has its own thresholds, and a transitional record is exactly where a terminology gap causes confusion.

Situation	What to say
Routine follow-up	Nothing. Use “PCOS” and use the time for symptoms.
New clinician	“I have PCOS — recently renamed polyendocrine metabolic ovarian syndrome. Same diagnosis, either name is fine.”
Told your scan looks normal	“My diagnosis was made on irregular cycles and androgen excess, not on the ultrasound. Can we go through which criteria I met?”
A letter or portal note uses PMOS and you did not expect it	“Is PMOS on this letter the same as the PCOS on my old notes?” — the answer is yes.
Referral to a new specialty	“Please note both terms in the referral so nothing gets missed.”

Will your doctor already know?

Some will, some will not, and neither tells you anything about how good they are.

Adoption moves outward from the specialties that were in the room. Reproductive endocrinologists and the clinicians who follow the guideline work closely will have seen the announcement. A busy primary care doctor covering hundreds of conditions may not have, and the consensus group built a co-designed education programme and a formal transition period precisely because they expected that.

So if you say “PMOS” and get a blank look, it is not a red flag. Say “PCOS”, carry on with the appointment, and judge the clinician on whether they check your androgens and your glucose — not on whether they have read a naming paper.

Does this change anything about your phenotype?

No. The four Rotterdam phenotypes are defined by which two of the three features you have, and the rename left all three features and all four combinations exactly where they were.

It does land differently depending on which one you are, though. If you were diagnosed on irregular ovulation plus androgen excess — phenotype B, with no polycystic-appearing ovaries on imaging — the old name was never accurate for you, and you are the person most likely to have been told “but your scan is fine”. For you, the new name is a small piece of leverage in a conversation you have probably had before.

If your ultrasound did show the classic picture, nothing about the change affects how you are described, treated or followed.

The features themselves are worth knowing cold either way: see the Rotterdam criteria and the current PMOS diagnosis criteria.

What to use the appointment for instead

Terminology is the cheapest thing you can bring to a consultation. The expensive thing — the part that reliably goes wrong — is the information you leave without.

In a survey of 1,385 women published in 2017, 33.6% reported waiting more than two years for a diagnosis, 47.1% saw three or more health professionals before getting one, and only 15.6% were satisfied with the information they received at diagnosis. That is the gap worth spending your ten minutes on.

So bring one of these instead:

• Which criteria did I actually meet? Ask for the specific two of three, in writing.
• When were my androgens, glucose and lipids last checked? The condition affects about one in eight women and carries metabolic risk that needs periodic rechecking, not a single baseline.
• What is the plan for the symptom that bothers me most? Name one. Not five.
• What should trigger a recheck or a referral? Get the threshold, not a vague “come back if it gets worse.”

Your next step

Open the notes app on your phone and write one line: “PCOS — now also called polyendocrine metabolic ovarian syndrome (PMOS). Diagnosed on: ____ and ____.” Fill in the two criteria you met. If you do not know them, that blank is your next appointment question — and it is a far better use of the visit than a vocabulary update.

Then read the rest of the diagnosis section with both words in your head. You will see them used interchangeably for years, because that is exactly what the transition was designed to do.